Eli Lilly and Company logo

Eli Lilly and (LLY) stock

LLY · Eli Lilly and Company · NYSE

Website
Market cap
$1.27T
P/E
43.8
EPS (TTM)
$30.81
Shares out
940.7M
52-week range80% up the range
$850.64$1474.71

What is the latest news on LLY stock?

LLY fell 0.24% to $1348.20 on Nov 20, 2026. No LLY story in the last two days; the most recent is below.

PRago
Gold, Silver and Crude Slide Hard as Volatility Jumps on the Week

VANCOUVER, BC, Nov. 18, 2026 /CNW/ -- Stock Preachers News Commentary - Major indices were mixed as of midday Wednesday, with the Dow down sharply and the Nasdaq Composite little changed to higher on the day even as all four benchmarks remain lower on the week. Gold, silver and crude oil all fell sharply on the day and the week, while the CBOE Volatility Index eased on the day but jumped on the week. Against that backdrop, cybersecurity and semiconductor-linked names drew attention, led by Cisco's latest quarterly results. Active Companies from around the markets with current developments this week include: Cisco (NASDAQ:CSCO), Alimentation Couche-Tard Inc. (TSX:ATD), Eli Lilly and Company (

All LLY news
Price$1348.20+102.65 (+8.24%)
2026-08-202026-11-20

Who owns the most LLY stock?

Lilly Endowment Inc was the largest reported holder of LLY at the end of Q2 2026, with 90,376,978 shares worth $108.4 billion. Next came BlackRock, Inc. ($81.0 billion) and Vanguard Capital Management LLC ($64.2 billion). In all, 4,619 institutions reported $943.6 billion of LLY in their 13F filings.

All LLY fund holders

Are insiders buying or selling LLY?

Insiders are selling. In the last 90 days 1 insider sold $7.0 million of LLY in trades reported on Form 4. The latest: Anat Hakim sold $7.0 million, reported on Nov 3, 2026.

LLY insider trades

Financial highlights

Full financials
Revenue, TTM
$86.46B
Revenue growth
+45.5%
Net income, TTM
$27.58B
Net margin
31.9%
Cash
$4.88B

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items

LLY rankings

News · 26 weeks134+38%
2026-05-31: 22026-06-07: 42026-06-14: 42026-06-21: 62026-06-28: 22026-07-05: 02026-07-12: 32026-07-19: 82026-07-26: 02026-08-02: 52026-08-09: 42026-08-16: 72026-08-23: 22026-08-30: 32026-09-06: 22026-09-13: 32026-09-20: 62026-09-27: 112026-10-04: 42026-10-11: 42026-10-18: 92026-10-25: 92026-11-01: 112026-11-08: 102026-11-15: 152026-11-22: 0
2026-05-312026-11-22
Mix8990d
  • Other50(56%)
  • Insider31(35%)
  • Dividends3(3%)
  • Earnings2(2%)
  • SEC Filings2(2%)
  • Analyst1(1%)
Activity · 52 weeks289133 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Our reporting on LLY

Eli Lilly and Company (LLY) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 47 wire items for LLY, including 21 insider trades, 20 press releases and news items and 3 dividend updates. The most recent was published Nov 19, 2026.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

LLY FAQ

9 questions
  • What does Eli Lilly and Company do?
    Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer...
  • What is LLY revenue?
    Eli Lilly and Company (LLY) reported $86.46B of revenue for the twelve months ended Sep 30, 2026. That is up 45.5% from the year before. Revenue for fiscal 2025 was $65.18B.
  • Is LLY profitable?
    Yes. Eli Lilly and Company earned $27.58B in net income for the twelve months ended Sep 30, 2026, a net margin of 31.9%.
  • How much cash and debt does LLY have?
    Eli Lilly and Company reported $4.88B in cash and cash equivalents and $49.50B of debt on its most recent balance sheet in SEC filings.
  • Where does LLY stock trade?
    Eli Lilly and Company (LLY) is listed on NYSE.
  • What sector and industry is LLY in?
    Eli Lilly and Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about LLY?
    Across the last 8 analyst actions on Eli Lilly and Company, there were 2 upgrades and 1 downgrade. The most recent action was from Berenberg: Buy with a $1400.00 price target on 2026-09-15. Recent price targets range from $850.00 to $1400.00.
  • What companies are similar to LLY?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), NVO (Novo Nordisk A/S), AMGN (Amgen Inc.). Compare LLY side-by-side with any of them on Quantisnow.
  • How can I track LLY on Quantisnow?
    Quantisnow aggregates Eli Lilly and Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LLY to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change